Xenon Pharma Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Published: Aug 04, 2017

BURNABY, British Columbia, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended June 30, 2017, and provided a corporate update for 2017.

Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “We remain focused on our strategy to develop ion channel modulators, backed by strong human genetic validation, for neurological disorders. Both of our proprietary programs, XEN1101 and XEN901, are highly differentiated molecules being developed as anti-epileptic drugs. We have also partnered with collaborators at Genentech to advance a novel, selective oral Nav1.7 inhibitor for the treatment of pain.”

Back to news